Ignite Creation Date:
2024-05-06 @ 7:13 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05934045
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-07-06
First Post:
2023-06-23
Brief Title:
Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma
Sponsor:
University Hospital Toulouse
Organization:
University Hospital Toulouse
Study Overview
Official Title:
Deciphering the Role of Circular RNAs in the Pathogenesis and Therapy Resistance of ALKpositive Anaplastic Large-cell Lymphoma
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CIRComa
Brief Summary:
The objective of thE project is to determine whether circRNAs could be used as circulating prognostic andor predictive biomarkers of ALK ALCL resistance to treatment and whether they can be exploited as therapeutic targets
Detailed Description:
Anaplastic large-cell lymphoma ALCL is an aggressive T-cell pediatric lymphoma 85 of ALK ALCL cases harbor a fusion between the nucleophosmin NPM and anaplastic lymphoma kinase ALK genes leading to a constitutively activated and oncogenic fusion protein Most ALK ALCL cases initially respond well to the frontline chemotherapy but 30 of patients relapse and are of poor prognosis Understanding the origins of therapy resistance is of major importance to improve treatment and patient prognosis Current research highlights deregulated expression of regulatory non-coding RNAs ncRNAs as an important factor in therapy resistance To date microRNAs and long noncoding RNAs have been linked to therapy resistance in ALK ALCL Circular RNAs circRNAs are a class of highly stable noncoding RNAs that have recently come into the focus of researchers circRNAs can control target gene expression by eg interacting with microRNAs or proteins This project aims to elucidate their role in ALK ALCL biology including their impact on noncoding RNA networks and therapy resistance This project will 1 identify a signature of circRNAs associated with therapy resistance in ALK ALCL 2 analyze their effect on treatment response 3 elucidate their mechanism of action and 4 evaluate circRNA candidates as predictive and prognostic plasma biomarkers using liquid biopsies The goal of the study is to characterize the role of candidate circRNAs in this well-defined cancer type which can serve as a model for other ALK cancers Project results will add to the current mechanistic understanding of ALK ALCL pathogenesis and the origins of therapy resistance and could define new druggable targets and associated predictive biomarkers for high-risk disease Establishing the blood-based alternative confirmation for the ALK ALCL diagnosis could also produce a less invasive predictive tool capable of longitudinal patient monitoring for early relapse detection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| French Ministry of Health | OTHER_GRANT | PRT-K22-051 | None |